TriSalus Life Sciences (NASDAQ:TLSI) Earns “Buy” Rating from Roth Mkm

TriSalus Life Sciences (NASDAQ:TLSI)‘s stock had its “buy” rating reissued by equities research analysts at Roth Mkm in a research note issued to investors on Friday,Benzinga reports. They currently have a $11.00 price target on the stock. Roth Mkm’s target price would indicate a potential upside of 112.60% from the company’s current price.

TLSI has been the subject of several other reports. Canaccord Genuity Group decreased their price objective on shares of TriSalus Life Sciences from $12.00 to $11.00 and set a “buy” rating for the company in a research note on Friday, November 15th. Roth Capital raised shares of TriSalus Life Sciences to a “strong-buy” rating in a research report on Monday, November 11th. Northland Securities assumed coverage on shares of TriSalus Life Sciences in a report on Friday, October 25th. They issued an “outperform” rating and a $12.50 price target on the stock. Northland Capmk raised shares of TriSalus Life Sciences to a “strong-buy” rating in a report on Friday, October 25th. Finally, Cantor Fitzgerald assumed coverage on shares of TriSalus Life Sciences in a report on Tuesday, December 17th. They issued an “overweight” rating and a $10.00 price target on the stock. Seven equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, TriSalus Life Sciences currently has an average rating of “Buy” and an average price target of $11.79.

TriSalus Life Sciences Stock Performance

TriSalus Life Sciences stock traded up $0.01 during trading on Friday, reaching $5.17. The company had a trading volume of 6,785 shares, compared to its average volume of 17,977. TriSalus Life Sciences has a 12-month low of $3.50 and a 12-month high of $10.42. The stock’s 50 day moving average price is $4.48 and its two-hundred day moving average price is $4.77. The firm has a market capitalization of $157.76 million, a price-to-earnings ratio of -2.08 and a beta of 0.51.

Insider Activity at TriSalus Life Sciences

In other TriSalus Life Sciences news, major shareholder Equity Ab Frankenius acquired 62,972 shares of TriSalus Life Sciences stock in a transaction dated Tuesday, December 17th. The stock was bought at an average price of $3.97 per share, for a total transaction of $249,998.84. Following the transaction, the insider now owns 6,230,748 shares in the company, valued at approximately $24,736,069.56. This trade represents a 1.02 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders purchased 70,012 shares of company stock worth $281,235 in the last 90 days. Corporate insiders own 32.80% of the company’s stock.

Hedge Funds Weigh In On TriSalus Life Sciences

Several large investors have recently made changes to their positions in the business. Walleye Capital LLC bought a new position in shares of TriSalus Life Sciences during the 3rd quarter valued at about $66,000. Virtu Financial LLC purchased a new stake in TriSalus Life Sciences during the third quarter valued at about $92,000. Vestcor Inc purchased a new stake in TriSalus Life Sciences during the third quarter valued at about $108,000. MSD Partners L.P. purchased a new stake in TriSalus Life Sciences during the third quarter valued at about $184,000. Finally, Geode Capital Management LLC lifted its stake in TriSalus Life Sciences by 45.4% during the third quarter. Geode Capital Management LLC now owns 200,427 shares of the company’s stock valued at $924,000 after buying an additional 62,542 shares in the last quarter. Institutional investors own 2.58% of the company’s stock.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.